Oral presentation by Dr. Nancy U. Lin from Dana-Farber Cancer Institute at 8:55 a.m. CEST/2:55 a.m. ET on October 22, 2023Olema will host an investor conference call at 8:00 a.m. ET on October 23,.
Olema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Amended clinical collaboration and supply agreement increases the palazestrant/ribociclib combination Phase 1/2 clinical study size to approximately 60 patients Expanded study supports the potential.
SAN FRANCISCO, Sept. 20, 2023 (GLOBE NEWSWIRE) Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and